Related Experiment Video
Updated: Sep 16, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Oncogenic YAP sensitizes cells to CHK1 inhibition via CDK4/6 driven G1 acceleration
Dörthe Gertzmann1, Cornelius Presek1, Anna Lena Mattes1
1Department of Biochemistry and Cell Biology, Theodor Boveri Institute, Biocenter, Julius Maximilian University Würzburg, Am Hubland, 97074, Würzburg, Germany.
Abstract:
Replication stress is a driver of genomic instability, contributing to carcinogenesis by causing DNA damage and mutations. While YAP, the downstream co-activator of the Hippo signaling pathway, plays a crucial role in regulating cell growth and differentiation, it is unclear whether it generates replication stress exploitable for therapy. Here, we report that oncogenic YAP shortens the G1 phase through increased CDK4/6 activity, leading to early S-phase entry. This causes origin underlicensing, an overall reduced rate of DNA replication, and, unusually, an accelerated speed of individual replication forks. CHK1 inhibition in cells expressing oncogenic YAP results in DNA damage during S-phase, which is not due to premature CDK1 activation or mitotic entry. Sensitivity to CHK1 inhibition depends on the YAP-TEAD interaction and involves a global increase in transcription and an increase in transcription-replication conflicts (TRCs). Replication stress from oncogenic YAP can be mitigated by restoring G1 length through partial CDK4/6 inhibition or by reducing YAP-induced hypertranscription. Our findings suggest a potential therapeutic strategy for targeting YAP-dependent cancers by exploiting their vulnerability to replication stress.
Insights
Oncogenic YAP causes replication stress by shortening G1 phase, leading to DNA damage. Targeting this vulnerability with CHK1 inhibitors offers a potential therapeutic strategy for YAP-dependent cancers.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Replication stress drives genomic instability and cancer by causing DNA damage and mutations.
- The Hippo signaling pathway's co-activator, YAP, regulates cell growth and differentiation, but its role in generating therapy-exploitable replication stress is unknown.
Purpose of the Study:
- To investigate whether oncogenic YAP generates replication stress that can be therapeutically exploited.
- To elucidate the mechanisms by which YAP induces replication stress and identify potential therapeutic vulnerabilities.
Main Methods:
- Analysis of cell cycle progression and DNA replication dynamics in cells expressing oncogenic YAP.
- Assessment of DNA damage and sensitivity to CHK1 inhibition in YAP-expressing cells.
- Investigation of the role of YAP-TEAD interaction, transcription, and transcription-replication conflicts (TRCs) in YAP-induced replication stress.
Main Results:
- Oncogenic YAP shortens G1 phase via CDK4/6, causing early S-phase entry, origin underlicensing, and accelerated replication fork speed.
- CHK1 inhibition in YAP-expressing cells leads to S-phase DNA damage, dependent on YAP-TEAD interaction, global transcription increase, and heightened TRCs.
- YAP-induced replication stress can be alleviated by restoring G1 length or reducing YAP-driven hypertranscription.
Conclusions:
- Oncogenic YAP induces a unique form of replication stress characterized by accelerated replication fork speed and increased transcription-replication conflicts.
- Targeting YAP-dependent cancer cells by exploiting their vulnerability to replication stress, particularly through CHK1 inhibition or modulation of transcription, presents a promising therapeutic avenue.
Related Concept Videos
Inhibition of Cdk Activity
DNA Damage can Stall the Cell Cycle
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle
Positive Regulator Molecules
Negative Regulator Molecules

